

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 20, 2022 ( May 19, 2022)

**SPRINGWORKS THERAPEUTICS, INC.**  
(Exact name of registrant as specified in its charter)

Delaware  
(State or other jurisdiction  
of incorporation)

001-39044  
(Commission  
File Number)

83-4066827  
(I.R.S. Employer  
Identification No.)

100 Washington Blvd  
Stamford, CT 06902  
(Address of principal executive offices, including zip code)

(203) 883-9490  
(Registrant's telephone number, including area code)

Not Applicable  
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value \$0.0001 per share	SWTX	The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 5.07. Submission of Matters to a Vote of Security Holders.**

On May 19, 2022, SpringWorks Therapeutics, Inc. (the “Company”) held its annual meeting of stockholders to consider and vote on the proposals set forth below, each of which is described in greater detail in the Company’s definitive proxy statement filed with the U.S. Securities and Exchange Commission on April 8, 2022. The final voting results are set forth below.

**Proposal 1 - Election of Directors**

The stockholders elected each of the three persons named below to serve as a Class III director of the Company for a three-year term that expires at the Company’s annual meeting of stockholders in 2025 and until his or her successor has been duly elected and qualified, subject to his or her earlier death, resignation or removal. The results of such vote were as follows:

<b>Director Name</b>	<b>Votes For</b>	<b>Withheld</b>	<b>Abstentions/ Non-Votes</b>
Alan Fuhrman	27,686,399	6,817,282	7,972,512
Julie Hambleton, M.D.	27,767,167	6,736,514	7,972,512
Daniel S. Lynch, M.B.A.	23,219,010	11,284,671	7,972,512

**Proposal 2 - Ratification of Appointment of Independent Registered Public Accounting Firm**

The stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022. The results of such vote were as follows:

<b>Votes For</b>	<b>Votes Against</b>	<b>Abstentions</b>
42,248,351	220,017	7,825

**Proposal 3 - Non-Binding Advisory Vote on Executive Compensation**

The stockholders approved, on a non-binding advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Company’s proxy statement for the annual meeting of stockholders. The results of such vote were as follows:

<b>Votes For</b>	<b>Votes Against</b>	<b>Abstentions/ Non-Votes</b>
26,157,025	8,338,675	7,980,493

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SpringWorks Therapeutics, Inc.

Date: May 20, 2022

By: /s/ Francis I. Perier, Jr.

Francis I. Perier, Jr.  
Chief Financial Officer

---